Compare IMMP & MRAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | MRAM |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 214.4M |
| IPO Year | N/A | 2016 |
| Metric | IMMP | MRAM |
|---|---|---|
| Price | $2.90 | $9.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | ★ 1.9M | 156.4K |
| Earning Date | 02-22-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,306,742.00 | ★ $53,642,000.00 |
| Revenue This Year | $292.48 | $11.00 |
| Revenue Next Year | N/A | $9.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.28 | N/A |
| 52 Week Low | $1.32 | $4.34 |
| 52 Week High | $3.53 | $12.27 |
| Indicator | IMMP | MRAM |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 57.34 |
| Support Level | $2.52 | $9.03 |
| Resistance Level | $3.32 | $9.55 |
| Average True Range (ATR) | 0.22 | 0.41 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 62.18 | 83.20 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).